SCHEMBL9786210

SCHEMBL9786210

C=CCO[C@H]1O[C@@H]2COC(C)(C)O[C@H]2[C@H](O)[C@H]1NC(=O)OCC(Cl)(Cl)Cl

nearest known ligand 0.32

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ CA1 P00915 1/20 0.31
▸ CA2 P00918 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1743867 0.87 — —
SCHEMBL2803932 0.87 — —
SCHEMBL9786206 0.86 — —
SCHEMBL7567193 0.85 ALDH1A1 (0.36) ALDH1A1CA1CA2
SCHEMBL7886992 0.85 ALDH1A1 (0.36) ALDH1A1CA1CA2
SCHEMBL7889397 0.85 ALDH1A1 (0.36) ALDH1A1CA1CA2
SCHEMBL7571242 0.85 ALDH1A1 (0.32) ALDH1A1POLBCA1CA2
SCHEMBL4162965 0.85 ALDH1A1 (0.32) ALDH1A1POLBCA1CA2
SCHEMBL4160816 0.85 ALDH1A1 (0.32) ALDH1A1POLBCA1CA2
SCHEMBL9625028 0.83 ALDH1A1 (0.37) ALDH1A1POLBCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240002425-A1 NOVEL AMINOALKYL GLUCOSAMINIDE 4-PHOSPHATE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2024-01-04 — — US disclosed
EP-4245763-A1 NOVEL AMINOALKYL GLUCOSAMINIDE 4-PHOSPHATE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2023-09-20 — — EP disclosed
US-5066794-A Coupling monosaccharides, phosphonation, protecting, deprotecting DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1991-11-19 — — US disclosed
EP-0172581-A2 Disaccharide derivatives DAIICHI SEIYAKU CO., LTD. (JP) 1986-02-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240002425-A1 NOVEL AMINOALKYL GLUCOSAMINIDE 4-PHOSPHATE DERIVATIVE TLR4, TLR5, TLR9 ALDH1A1 3605/4885POLB 4248/4885CA1 4012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback